Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients

References

• SlamonDJClarkGMWongSGLevinWJUllrichAMcGuireWLHuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience19872351771823798106
   PubMed Web of Science ®Google Scholar
• SlamonDJGodolphinWJonesLAStudies of the HER-2/neu proto-oncogene in human breast and ovarian cancerScience19892447077122470152
   PubMed Web of Science ®Google Scholar
• GustersonBAGelberRDGoldhirschAPrognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study GroupJ Clin Oncol199210104910561351538
   PubMed Web of Science ®Google Scholar
• SeshadriRFirgairaFAHorsfallDJMcCaulKSetlurVKitchenPClinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study GroupJ Clin Oncol199311193619428105035
   PubMed Web of Science ®Google Scholar
• RavdinPMChamnessGCThe c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers – a reviewGene199515919277607568
   PubMed Web of Science ®Google Scholar
• PressMFBernsteinLThomasPAHER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomasJ Clin Oncol199715289429049256133
   PubMed Web of Science ®Google Scholar
• VermaSMilesDGianniLTrastuzumab emtansine for HER2-positive advanced breast cancerN Engl J Med20123671783179123020162
   PubMed Web of Science ®Google Scholar
• AogiKAndoMIwataHHaraFMatsubaraMFujiwaraYPhase I study of single agent trastuzumab emtansine in japanese patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (JO22591)Cancer Res201171Suppl 24 Abstr nr P1-12-19
   Google Scholar
• KropIEBeeramMModiSPhase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancerJ Clin Oncol2010282698270420421541
   PubMed Web of Science ®Google Scholar
• BurrisHA3rdRugoHSVukeljaSJPhase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapyJ Clin Oncol20112939840521172893
   PubMed Web of Science ®Google Scholar
• MasudaNItoYTakaoSA multicenter Phase 2 study (JO22997) evaluating the efficacy and safety of trastuzumab emtansine in japanese patients with heavily pretreated HER2-positive metastatic breast cancerCancer Res201272Suppl 24 Abstr nr P5-18-16
   Google Scholar
• KropIELoRussoPMillerKDA Phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabineJ Clin Oncol2012303234324122649126
   PubMed Web of Science ®Google Scholar
• BeeramMKropIEBurrisHAA Phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancerCancer20121185733574022648179
   PubMed Web of Science ®Google Scholar
• BenderBCSchaedeli-StarkFKochRA population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancerCancer Chemother Pharmacol20127059160122886072
   PubMed Web of Science ®Google Scholar
• GirishSGuptaMWangBClinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancerCancer Chemother Pharmacol2012691229124022271209
   PubMed Web of Science ®Google Scholar
• IwataHHoriguchiJSatoNFujiwaraYA Phase Ib trial of trastuzumab emtansine in combination with pertuzumabJapan Society of Clinical Oncology2013 Abstr O10-5. Available from: http://jsco.members-web.com/51award_eng/ct_04.phpAccessed February 23, 2014
   Google Scholar
• BaselgaJCortesJKimSBPertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerN Engl J Med201236610911922149875
   PubMed Web of Science ®Google Scholar
• Hoffmann-La RocheA Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE) Available from: http://clinicaltrials.gov/show/NCT01120184. NLM identifier: NCT01120184Accessed March 17, 2014
   Google Scholar
• GenentechA Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer (CLEOPATRA) Available from: http://clinicaltrials.gov/ct2/show/NCT00567190. NLM identifier: NCT00567190Accessed January 22, 2014
   Google Scholar
• Hoffmann-La RocheA Study of Trastuzumab Emtansine in Comparison With Treatment of Physician’s Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA) Available from: http://clinicaltrials.gov/show/NCT01419197. NLM identifier: NCT01419197Accessed January 6, 2014
   Google Scholar
• Hoffmann-La RocheA Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer Available from: http://clinicaltrials.gov/show/NCT01966471. NLM identifier: NCT01966471Accessed March 17, 2014
   Google Scholar
• Hoffmann-La RocheA Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer Available from: http://clinicaltrials.gov/ct2/show/NCT01358877?term=NCT01358877&rank=1. NLM identifier: NCT01358877Accessed March 17, 2014
   Google Scholar
• Hoffmann-La RocheA Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) Available from: http://clinicaltrials.gov/ct2/show/NCT01772472?term=NCT01772472&rank=1. NLM identifier: NCT01772472Accessed March 17, 2014
   Google Scholar
• HurvitzSADirixLKocsisJPhase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancerJ Clin Oncol2013311157116323382472
   PubMed Web of Science ®Google Scholar